BVCF

Qiselian Biotech focuses on personalized cell therapy and anti-aging. Based on the new generation of induced pluripotent stem cell (iPSC) technology, it develops innovative products and services for autologous cell therapy, regenerative medicine and health management.

VivaLnk specializes in connected healthcare solutions aimed at enhancing both in-patient and remote patient monitoring. The company offers a range of wearable medical-grade devices and data analytics applications that provide continuous health monitoring for individuals, thereby improving healthcare quality and accessibility worldwide. Founded in 2014, VivaLnk developed eSkin, a pioneering breathable thin film substrate embedded with integrated circuits and sensors, designed for long-term wear. Through its innovative technology and analytics, the company seeks to facilitate remote monitoring and improve overall patient care in the realms of wellness and telemedicine.

Cellenkos is a clinical-stage biotechnology company dedicated to developing and commercializing innovative allogeneic T-regulatory cell therapies aimed at treating autoimmune and inflammatory disorders. By utilizing umbilical cord blood-derived T-regulatory cells, Cellenkos seeks to create biopharmaceutical products that provide healthcare providers with effective treatment options for patients suffering from these conditions. The company's focus on early-stage clinical biotechnology positions it to address significant unmet medical needs in the field of autoimmune disease management.

Oculis is a global biopharmaceutical company focused on advancing eye care and preserving vision through innovative drug delivery solutions. The company's unique platform enables effective drug absorption in both the anterior and posterior segments of the eye, allowing for the treatment of conditions such as diabetic macular edema (DME) with a simple topical application, thus eliminating the need for invasive procedures. Oculis is developing several therapeutic candidates, including OCS-01, a topical treatment for DME; OCS-02, aimed at addressing dry eye disease; and OCS-05, which targets acute optic neuritis and other neuro-ophthalmic disorders. This novel approach not only facilitates treatment for posterior eye diseases but also reduces the required frequency of applications for anterior conditions compared to traditional eye drops.

Drug Farm Inc. is a biotech company based in Shanghai, China, engaged in the development of innovative drugs and technologies for metabolic diseases such as obesity, diabetes, and fatty liver, as well as targeting innate immunity for conditions like HBV, cancer, and autoimmune diseases. The company employs its unique IDInVivo platform, which integrates advanced genetics and artificial intelligence to identify novel drug targets through genetic screens in living animals with intact immune systems. By leveraging various AI methodologies, including supervised learning, active learning, and reinforcement learning, Drug Farm aims to accelerate the medicinal chemistry development process, ultimately striving to deliver first-in-class therapeutic solutions to the healthcare industry.

Boan Biotech is a fully integrated biopharmaceutical company specializing in the development, manufacture, and commercialization of therapeutic antibodies. The company focuses on several key therapeutic areas, including oncology, metabolism, autoimmunity, and ophthalmology. While it primarily generates revenue from customers in Mainland China, Boan Biotech aims to expand its reach globally. The company is committed to delivering high-quality biologics to address unmet medical needs in these critical fields.

GenEros Biopharma is a biopharmaceutical company that develops autoimmune and anti-inflammation therapeutics.

Seinda is a company that specializes in developing a point-of-care diagnosis platform for ophthalmic conditions. The firm focuses on creating diagnostic kits and testing machinery tailored for various eye disorders, including Dry Eye Disease. By enhancing the capabilities of healthcare professionals, Seinda aims to improve the identification and treatment of patients with eye diseases. The company is dedicated to establishing an open ophthalmic omics platform and conducting research on the molecular mechanisms of eye diseases. In addition to developing innovative diagnostic and therapeutic products, Seinda seeks to address clinical needs and build a prominent brand in the ophthalmic sector.

BioNTech is a Germany-based biotechnology company that specializes in developing innovative immunotherapies for cancer and other serious diseases, as well as vaccines for infectious diseases, including COVID-19. The company’s oncology pipeline includes a range of drug classes, such as mRNA-based drugs that encode antigens and neoantigens, cell therapies, bispecific antibodies, and antibody-drug conjugates. BioNTech has established partnerships with several major pharmaceutical companies, enhancing its research and development capabilities. Its COVID-19 vaccine, Comirnaty, represents its first commercialized product, demonstrating the company's commitment to addressing urgent health challenges through advanced therapeutic approaches.

AcuVu develops an endoscopy platform that makes diagnostic and surgical endoscopy procedures easy to perform and reduces the medical cost. In addition, the platform's high-quality digital imaging can be transmitted through high-speed Internet that provides tools for remote medical diagnostic.

Wekair specializes in providing intervention services for children with developmental disorders, including Autism Spectrum Disorder (ASD), ADHD, and language learning delays. The company offers both online and offline support, featuring an online platform for ASD screening and computer-aided diagnosis tools for healthcare professionals. Wekair also delivers individualized consultations and fosters community support for families, aiming to improve the quality of life for children with these challenges. By combining technology with personalized care, Wekair seeks to enhance the rehabilitation and developmental outcomes for its young clients.

Stealth BioTherapeutics is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of therapies targeting diseases linked to mitochondrial dysfunction. Founded in 2006 and based in George Town, Cayman Islands, the company is advancing its lead product candidate, Elamipretide, which aims to address both rare genetic and age-related mitochondrial diseases. Additionally, Stealth BioTherapeutics is developing SBT-20, a small peptide that stabilizes mitochondrial structure and function during oxidative stress, and SBT-272, a compound under evaluation for rare neurodegenerative diseases, including amyotrophic lateral sclerosis. Mitochondria play a crucial role in energy production and overall organ function, making the company's focus on these organelles significant in the biopharmaceutical landscape.

MicuRx Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing antibiotics to address drug-resistant bacterial infections. Founded in 2007 and headquartered in Palo Alto, California, the company has established a hybrid business model that leverages U.S. research and development alongside cost-effective scientific resources in China. MicuRx's product lineup includes MRX-I, an oral antibiotic targeting multi-drug resistant gram-positive pathogens, and its intravenous prodrug form, MRX-IV. Additionally, the company offers MRX-V, an injectable antibiotic for gram-negative bacteria, and MRX-VIII, a polymyxin for gram-negative infections. The company is also working on a pipeline of antibacterial drugs aimed at combating both gram-positive and gram-negative bacterial pathogens. MicuRx's subsidiary, Shanghai MicuRx, is responsible for commercializing its agents in China while global clinical studies continue.

Genova (Changzhou) Biotechnology Co., Ltd. is a biotechnology company based in Changzhou, China, specializing in the development and manufacturing of insulin products. The company is dedicated to producing advanced insulin formulations aimed at treating diabetes, cardiovascular, and cerebrovascular diseases, as well as tumors. Genova focuses on providing third-generation insulin drugs to enhance patient care and improve treatment outcomes.

Jiyuan Biotechnology is a biotechnology company focusing on the use of stem cell technology for unmet medical needs. The company focuses on innovative therapeutics gene-therapy development, high-end hospital medical service, and stem cell research. Jiyuan Biotechnology provides personalized medicine and high-end specialty healthcare in key fields including diabetes, cardiovascular diseases, and oncology.

Eucure Biopharma, established in 2016 and headquartered in Beijing, China, is a biotechnology company focused on the discovery and development of innovative immuno-oncology targeted antibodies. Its pipeline comprises eight drug candidates, primarily targeting immune checkpoints, with several in the clinical trial application stage. The company offers services such as antibody production, in vivo and in vitro drug efficacy testing, and operates as a subsidiary of Beijing Biocytogen Co., Ltd. Eucure Biopharma aims to improve the survival rate of tumor patients by developing effective antibody treatments.

Eucure Biopharma, established in 2016 and headquartered in Beijing, China, is a biotechnology company focused on the discovery and development of innovative immuno-oncology targeted antibodies. Its pipeline comprises eight drug candidates, primarily targeting immune checkpoints, with several in the clinical trial application stage. The company offers services such as antibody production, in vivo and in vitro drug efficacy testing, and operates as a subsidiary of Beijing Biocytogen Co., Ltd. Eucure Biopharma aims to improve the survival rate of tumor patients by developing effective antibody treatments.

Yidu Healthcare is a medical big-data company that develops a data intelligence infrastructure. Yidu Healthcare's platform processes multi-source healthcare data, generates full life cycle medical data of patients which can be traced and supervised, and builds real-world disease models by in-depth processing and analysis. It enables effective policy-making and precise healthcare regulations, efficient clinical research and effective hospital management, improved life sciences R&D and commercialization effectiveness, and intelligent personal health management.

ASLAN Pharmaceuticals, established in 2010 and based in Singapore, is a clinical-stage biopharmaceutical company focused on immunology and oncology. It develops innovative treatments, including a monoclonal therapy for atopic dermatitis and a small molecule inhibitor for cancer, aiming to transform patients' lives. The company collaborates with prominent pharmaceutical partners and operates as a subsidiary of ASLAN Pharmaceuticals Limited.

DiaCarta Inc. is a translational genomics and personalized diagnostics company based in Richmond, California, founded in 2011. The company specializes in highly sensitive detection technologies and diagnostic solutions, particularly for cancer. DiaCarta offers a variety of products, including QClamp-based gene mutation tests for mutations in genes such as KRAS, NRAS, EGFR, and BRAF, as well as tests for HPV E6/E7 mRNA related to cervical and head-neck cancers. Their portfolio includes cancer biomarker gene expression detection kits, PCR-ready lysis kits, and custom diagnostic assay development services. DiaCarta also provides sample testing and companion diagnostic development services. Its products are marketed through distributors in countries including Chile, India, and Turkey, and are utilized by hospitals, clinical laboratories, and biotechnology companies to enhance patient care through reliable cancer diagnostics.

CARsgen Therapeutics, Ltd. is a clinical-stage immunotherapy company based in Shanghai, China, focused on developing chimeric antigen receptor T-cell (CAR-T) therapeutics for various cancers, including liver, lung, stomach, and brain cancers. The company specializes in CAR-T technology that enables T cells to target and destroy cancer cells by recognizing specific cell surface proteins. Notably, CARsgen’s therapies are designed to treat late-stage hepatocellular carcinoma (HCC) and lung squamous cell carcinoma. The company has also made significant advancements in clinical trials, having completed the world's first dose-ascending injection tests for HCC and exclusive tests for glioblastoma multiforme (GBM) in China. CARsgen collaborates with institutions such as the Shanghai Cancer Institute and Shanghai Renji Hospital, and is supported by prominent venture capital funding, positioning it to introduce innovative cancer treatments both in China and globally.

Jaguar Health is a pharmaceutical company focused on developing and commercializing plant-based medicines for gastrointestinal (GI) diseases in humans and animals. Its primary product, Mytesi, is a first-in-class anti-secretory agent approved for managing HIV/AIDS-related diarrhea. Jaguar Health operates through two segments: Human Health, which generates most of its revenue, and Animal Health. The company's pipeline includes products like crofelemer for cancer therapy-related diarrhea and short bowel syndrome, as well as animal health products such as Canalevia for chemotherapy-induced diarrhea in dogs. Headquartered in San Francisco, California, Jaguar Health aims to address urgent global health needs with its plant-based prescription medicines.

Kunshan RiboQuark Pharmaceutical Technology Co., Ltd. develops siRNA based preclinical drug candidates. Its products include QPI-1007, an ocular neuroprotectant. The company also develops siRNA-based cosmetic product for the prevention of hair loss. The company was founded in 2012 and is based in Kunshan, China.

Suzhou Ribo Life Science Co., Ltd. specializes in the development of nucleic acid drugs utilizing RNA interference (RNAi) technology, with a particular focus on treating liver diseases. Founded in 2007 and based in Kunshan, China, the company engages in various aspects of drug development, including drug discovery, siRNA design and screening, chemical modification, delivery technology, pharmacodynamics and pharmacokinetics studies, safety evaluation, and clinical trials. Suzhou Ribo Life Science offers siRNA therapeutics targeting conditions such as Hepatitis B, breast carcinoma, liver fibrosis, liver carcinoma, and HIV. The company has established a strategic partnership with Quark Pharmaceuticals, Inc. to enhance its research and development capabilities.

Genova (Changzhou) Biotechnology Co., Ltd. is a biotechnology company based in Changzhou, China, specializing in the development and manufacturing of insulin products. The company is dedicated to producing advanced insulin formulations aimed at treating diabetes, cardiovascular, and cerebrovascular diseases, as well as tumors. Genova focuses on providing third-generation insulin drugs to enhance patient care and improve treatment outcomes.

MicuRx Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing antibiotics to address drug-resistant bacterial infections. Founded in 2007 and headquartered in Palo Alto, California, the company has established a hybrid business model that leverages U.S. research and development alongside cost-effective scientific resources in China. MicuRx's product lineup includes MRX-I, an oral antibiotic targeting multi-drug resistant gram-positive pathogens, and its intravenous prodrug form, MRX-IV. Additionally, the company offers MRX-V, an injectable antibiotic for gram-negative bacteria, and MRX-VIII, a polymyxin for gram-negative infections. The company is also working on a pipeline of antibacterial drugs aimed at combating both gram-positive and gram-negative bacterial pathogens. MicuRx's subsidiary, Shanghai MicuRx, is responsible for commercializing its agents in China while global clinical studies continue.